182 related articles for article (PubMed ID: 15220340)
1. Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug pentostam.
Zhou Y; Messier N; Ouellette M; Rosen BP; Mukhopadhyay R
J Biol Chem; 2004 Sep; 279(36):37445-51. PubMed ID: 15220340
[TBL] [Abstract][Full Text] [Related]
2. Bifunctional role of the leishmanial antimonate reductase LmACR2 as a protein tyrosine phosphatase.
Zhou Y; Bhattacharjee H; Mukhopadhyay R
Mol Biochem Parasitol; 2006 Aug; 148(2):161-8. PubMed ID: 16644029
[TBL] [Abstract][Full Text] [Related]
3. Structural characterization of the As/Sb reductase LmACR2 from Leishmania major.
Mukhopadhyay R; Bisacchi D; Zhou Y; Armirotti A; Bordo D
J Mol Biol; 2009 Mar; 386(5):1229-39. PubMed ID: 18687336
[TBL] [Abstract][Full Text] [Related]
4. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action.
Sereno D; Cavaleyra M; Zemzoumi K; Maquaire S; Ouaissi A; Lemesre JL
Antimicrob Agents Chemother; 1998 Dec; 42(12):3097-102. PubMed ID: 9835497
[TBL] [Abstract][Full Text] [Related]
5. Crystallization and preliminary crystallographic characterization of LmACR2, an arsenate/antimonate reductase from Leishmania major.
Bisacchi D; Zhou Y; Rosen BP; Mukhopadhyay R; Bordo D
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2006 Oct; 62(Pt 10):976-9. PubMed ID: 17012788
[TBL] [Abstract][Full Text] [Related]
6. Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1.
Denton H; McGregor JC; Coombs GH
Biochem J; 2004 Jul; 381(Pt 2):405-12. PubMed ID: 15056070
[TBL] [Abstract][Full Text] [Related]
7. Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes.
Ephros M; Waldman E; Zilberstein D
Antimicrob Agents Chemother; 1997 May; 41(5):1064-8. PubMed ID: 9145870
[TBL] [Abstract][Full Text] [Related]
8. Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani.
Shaked-Mishan P; Ulrich N; Ephros M; Zilberstein D
J Biol Chem; 2001 Feb; 276(6):3971-6. PubMed ID: 11110784
[TBL] [Abstract][Full Text] [Related]
9. Gene amplification in Leishmania tarentolae selected for resistance to sodium stibogluconate.
Haimeur A; Ouellette M
Antimicrob Agents Chemother; 1998 Jul; 42(7):1689-94. PubMed ID: 9661005
[TBL] [Abstract][Full Text] [Related]
10. Leishmania mexicana: enzyme activities of amastigotes and promastigotes and their inhibition by antimonials and arsenicals.
Mottram JC; Coombs GH
Exp Parasitol; 1985 Apr; 59(2):151-60. PubMed ID: 2982638
[TBL] [Abstract][Full Text] [Related]
11. Biochemistry of Pentostam resistant Leishmania.
Berman JD; Edwards N; King M; Grogl M
Am J Trop Med Hyg; 1989 Feb; 40(2):159-64. PubMed ID: 2537584
[TBL] [Abstract][Full Text] [Related]
12. The synergistic action of pyrazolopyrimidines and pentavalent antimony against Leishmania donovani and L. braziliensis.
Martinez S; Looker DL; Berens RL; Marr JJ
Am J Trop Med Hyg; 1988 Sep; 39(3):250-5. PubMed ID: 2845824
[TBL] [Abstract][Full Text] [Related]
13. Glucantime resistant Leishmania promastigotes are sensitive to pentostam.
Moreira ES; Guerra JB; Petrillo-Peixoto Mde L
Rev Soc Bras Med Trop; 1992; 25(4):247-50. PubMed ID: 1340539
[TBL] [Abstract][Full Text] [Related]
14. Leishmania spp.: development of pentostam-resistant clones in vitro by discontinuous drug exposure.
Grögl M; Oduola AM; Cordero LD; Kyle DE
Exp Parasitol; 1989 Jul; 69(1):78-90. PubMed ID: 2543590
[TBL] [Abstract][Full Text] [Related]
15. In vitro antileishmanial properties of tri- and pentavalent antimonial preparations.
Roberts WL; Berman JD; Rainey PM
Antimicrob Agents Chemother; 1995 Jun; 39(6):1234-9. PubMed ID: 7574507
[TBL] [Abstract][Full Text] [Related]
16. Species-specific antimonial sensitivity in Leishmania is driven by post-transcriptional regulation of AQP1.
Mandal G; Mandal S; Sharma M; Charret KS; Papadopoulou B; Bhattacharjee H; Mukhopadhyay R
PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003500. PubMed ID: 25714343
[TBL] [Abstract][Full Text] [Related]
17. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes.
Ephros M; Bitnun A; Shaked P; Waldman E; Zilberstein D
Antimicrob Agents Chemother; 1999 Feb; 43(2):278-82. PubMed ID: 9925518
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of multidrug resistance in Plasmodium and Leishmania: detection of P-glycoprotein-like components.
Grogl M; Martin RK; Oduola AM; Milhous WK; Kyle DE
Am J Trop Med Hyg; 1991 Jul; 45(1):98-111. PubMed ID: 1678253
[TBL] [Abstract][Full Text] [Related]
19. Antimony susceptibility of Leishmania isolates collected over a 30-year period in Algeria.
Eddaikra N; Ait-Oudhia K; Kherrachi I; Oury B; Moulti-Mati F; Benikhlef R; Harrat Z; Sereno D
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006310. PubMed ID: 29561842
[TBL] [Abstract][Full Text] [Related]
20. ABCI3 Is a New Mitochondrial ABC Transporter from Leishmania major Involved in Susceptibility to Antimonials and Infectivity.
Arcari T; Manzano JI; Gamarro F
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28971869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
